Neoadjuvant, Adjuvant Data Provide Evidence of Curative Potential in Advanced Melanoma

Source: OncLive, October 2020

Long-term data presented at the 2020 ASCO Virtual Scientific Program demonstrated sustained relapse-free survival (RFS) benefit with adjuvant therapy in patients with advanced melanoma, providing further evidence of the curative potential of postoperative therapy, explained Michael B. Atkins, MD.

For example, findings from a 5-year analysis of the phase 3 COMBI-AD trial demonstrated a RFS rate of 52% (95% CI, 50%-60%) with the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) versus 36% (95% CI, 34%-43%) with placebo in patients with resected, stage III BRAF-mutant melanoma.1

Additional data from the meeting suggest that the role of neoadjuvant therapy is becoming more relevant, explained Atkins, displaying encouraging, long-term pathologic complete response (pCR) rates and high RFS rates.

READ THE ORIGINAL FULL ARTICLE